MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)

M.P. Goetz; M. Toi; J. Huober; J. Sohn; O. Tredan; I.H. Park; M. Campone; S.C. Chen; L.M. Manso Sanchez; S. Paluch-Shimon; G. van Hal; A. Shahir; H. Iwata; S. Johnston

doi:10.1016/j.annonc.2022.08.009

YUHSpace

BROWSE

0 184

Cited 0 times in

MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)

Authors: M.P. Goetz ; M. Toi ; J. Huober ; J. Sohn ; O. Tredan ; I.H. Park ; M. Campone ; S.C. Chen ; L.M. Manso Sanchez ; S. Paluch-Shimon ; G. van Hal ; A. Shahir ; H. Iwata ; S. Johnston